Back to Search
Start Over
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Mar; Vol. 146, pp. 84-86. Date of Electronic Publication: 2021 Feb 12. - Publication Year :
- 2021
- Subjects :
- Aged
Eccrine Porocarcinoma immunology
Eccrine Porocarcinoma metabolism
Eccrine Porocarcinoma pathology
ErbB Receptors genetics
ErbB Receptors metabolism
Humans
Male
Prognosis
Sweat Gland Neoplasms immunology
Sweat Gland Neoplasms metabolism
Sweat Gland Neoplasms pathology
Antineoplastic Agents, Immunological therapeutic use
Cetuximab therapeutic use
Drug Resistance, Neoplasm drug effects
Eccrine Porocarcinoma drug therapy
Immunotherapy adverse effects
Sweat Gland Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 146
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Report
- Accession number :
- 33588148
- Full Text :
- https://doi.org/10.1016/j.ejca.2021.01.012